Does Rallies show 13F holders for ACHV?

Yes. Rallies tracks hedge fund and 13F ownership data for ACHV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACHV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACHV. It does not provide personalized investment advice.

ACHV (Achieve Life Sciences, Inc.) Stock Analysis - Hedge Fund Holdings

Achieve Life Sciences, Inc. (ACHV) is a publicly traded Healthcare sector company. As of May 19, 2026, ACHV trades at $4.50 with a market cap of $489.68M and a P/E ratio of -3.61. ACHV moved -6.60% today. Year to date, ACHV is -10.46%; over the trailing twelve months it is +34.44%. Its 52-week range spans $1.84 to $6.15. Analyst consensus is strong buy with an average price target of $13.20. Rallies surfaces ACHV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACHV stock?

Hedge funds tracked by Rallies that own ACHV include Berkshire Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Achieve Life Sciences, Inc..

ACHV Key Metrics

Key financial metrics for ACHV
Metric	Value
Price	$4.50
Market Cap	$489.68M
P/E Ratio	-3.61
EPS	$-1.25
Dividend Yield	0.00%
52-Week High	$6.15
52-Week Low	$1.84
Volume	1.28M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-54.65M
Gross Margin	0.00%

Top Hedge Funds Holding ACHV

Berkshire Asset holds 17.70K shares of ACHV, changed +0.00% as of Sep 30, 2025.

Latest ACHV News

Achieve Life Sciences Shows 2.5% Nausea Rate in 52-Week Cytisinicline Safety Trial — May 19, 2026
Achieve Life Sciences Raises $354M, Names New CEO, Partners with Adare — May 12, 2026
Achieve Life Sciences Raises $354M in Private Placement, Appoints New CEO — Apr 16, 2026
Achieve Completes Analytical Transfer and First Engineering Batch for Cytisinicline at Adare’s Ohio Facility — Apr 15, 2026
Achieve Life Sciences Secures US Manufacturing for Cytisinicline Ahead of June 23 PDUFA — Mar 24, 2026

Recent ACHV Insider Trades

Oki Mark K sold 50.06K (~$146.18K) on Sep 18, 2025.
Stewart Richard Alistair sold 129.50K (~$378.14K) on Sep 18, 2025.
Wan Jerry sold 14.07K (~$38.97K) on Sep 4, 2025.

ACHV Analyst Consensus

5 analysts cover ACHV: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.20.

Common questions about ACHV

Who owns ACHV stock?: Hedge funds tracked by Rallies that own ACHV include Berkshire Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Achieve Life Sciences, Inc..
Does Rallies show 13F holders for ACHV?: Yes. Rallies tracks hedge fund and 13F ownership data for ACHV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACHV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACHV. It does not provide personalized investment advice.